Dr. Faltas Discusses Immunotherapy in Platinum-Resistant Bladder Cancer
Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses immunotherapy in platinum-resistant bladder cancer.
There are many early phase clinical trials that are trying to move immunotherapy as early in the spectrum of the disease as possible, says Faltas. He believes this will definitely have an impact on care for patients with bladder cancer.
Faltas says it is unlikely that immunotherapy alone is the answer to all patients with this disease; combinations with chemotherapeutic and targeted approaches should be considered.
Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses immunotherapy in platinum-resistant bladder cancer.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
